Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -370.16% is 1348% below its 5-year average of -25.56%, near the low end of its 5-year range (-370.16%–52.97%).
As of the fiscal period ended Tuesday, June 30, 2026. 73.28% below its 12-month average of -213.63%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -370.16%.
RETURN ON EQUITY (ROE)
-370.16%
RETURN ON EQUITY (ROE) AVG TTM
-213.63%
RETURN ON EQUITY (ROE) AVG 3Y
-59.92%
RETURN ON EQUITY (ROE) AVG 5Y
-25.56%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-73.28%
CURRENT VS 3Y AVG
-517.75%
CURRENT VS 5Y AVG
-1347.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-867.75%
vs the sector median at left
Co-Diagnostics, Inc.
Market Cap
$7.00M
Return on Equity (ROE)
-370.16%
TTM Avg
-213.63%
3Y Avg
-59.92%
5Y Avg
-25.56%
Market Cap
$6.85M
Return on Equity (ROE)
-108.00%
TTM Avg
-445.77%
3Y Avg
-254.63%
5Y Avg
-239.85%
Market Cap
$6.80M
Return on Equity (ROE)
-54.09%
TTM Avg
-388.62%
3Y Avg
-105.04%
5Y Avg
-44.72%
Market Cap
$7.01M
Return on Equity (ROE)
-111.46%
TTM Avg
-348.97%
3Y Avg
-374.13%
5Y Avg
-408.25%
Market Cap
$7.21M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$6.72M
Return on Equity (ROE)
-227.37%
TTM Avg
-118.13%
3Y Avg
-87.25%
5Y Avg
-55.09%
Market Cap
$7.31M
Return on Equity (ROE)
-1168.44%
TTM Avg
-606.51%
3Y Avg
-330.90%
5Y Avg
-270.23%
Market Cap
$6.41M
Return on Equity (ROE)
N/A
TTM Avg
-266.00%
3Y Avg
851.50%
5Y Avg
629.05%
Market Cap
$6.46M
Return on Equity (ROE)
-143.54%
TTM Avg
-132.34%
3Y Avg
-104.07%
5Y Avg
-91.90%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Co-Diagnostics, Inc. (CODX) | $7.00M | -370.16% | -213.63% | -59.92% | -25.56% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | -108.00% | -445.77% | -254.63% | -239.85% |
| Aclarion, Inc. (ACON)vs › | $6.80M | -54.09% | -388.62% | -105.04% | -44.72% |
| KALA BIO, Inc. (KALA)vs › | $7.01M | -111.46% | -348.97% | -374.13% | -408.25% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.21M | -218.65% | -54.74% | -35.36% | -35.36% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -227.37% | -118.13% | -87.25% | -55.09% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -1168.44% | -606.51% | -330.90% | -270.23% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.41M | N/A | -266.00% | 851.50% | 629.05% |
| Biomerica, Inc. (BMRA)vs › | $6.46M | -143.54% | -132.34% | -104.07% | -91.90% |
| Longeveron Inc. (LGVN)vs › | $7.64M | -225.67% | -236.53% | -220.64% | -186.37% |
ROE
-370.2%
ROA
-283.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -370.16% |
| 2026-03-31 | -302.34% |
| 2025-12-31 | -227.33% |
| 2025-09-30 | -80.80% |
| 2025-06-30 | -87.49% |
| 2025-03-31 | -74.83% |
| 2024-12-31 | -69.30% |
| 2024-09-30 | -64.73% |
| 2024-06-30 | -51.89% |
| 2024-03-31 | -49.63% |
| 2023-12-31 | -41.08% |
| 2023-09-30 | -42.78% |
| 2023-06-30 | -36.68% |
| 2023-03-31 | -28.66% |
| 2022-12-31 | -12.43% |
| 2022-09-30 | 11.24% |
| 2022-06-30 | 19.38% |
| 2022-03-31 | 27.40% |
| 2021-12-31 | 27.26% |
| 2021-09-30 | 41.90% |
| 2021-06-30 | 52.97% |
| 2021-03-31 | 67.46% |
| 2020-12-31 | 63.69% |
| 2020-09-30 | 52.93% |
| 2020-06-30 | 31.35% |
| 2020-03-31 | -30.74% |
| 2019-12-31 | -356.63% |
| 2019-09-30 | -192.22% |
| 2019-06-30 | -131.14% |
| 2019-03-31 | -113.77% |
| 2018-06-30 | -650.05% |
| 2018-03-31 | -294.85% |
| 2017-12-31 | -180.73% |
| 2017-09-30 | -115.23% |
